Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GFER | P55789 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30675273 | 1.00 | DDB1 (0.45) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL3668555 | 0.89 | DDB1 (0.42) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL7572544 | 0.88 | DDB1 (0.47) | DDB1CRBNNFKB1NFKB2RELA | |
| Hydrochloric Acid SCHEMBL6999487 | 0.86 | DDB1 (0.46) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL4043115 | 0.77 | GRIN2B (0.57) | CA1 | |
| Hydrochloric Acid SCHEMBL4053518 | 0.76 | GRIN2B (0.56) | CA1 | |
| SCHEMBL236978 | 0.74 | CARM1 (0.52) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL3696096 | 0.74 | CARM1 (0.52) | DDB1CRBNNFKB1NFKB2RELA | |
| SCHEMBL7723868 | 0.73 | GRIN2B (0.66) | MEN1KMT2ARAB9A | |
| Hydrochloric Acid SCHEMBL1170216 | 0.72 | CARM1 (0.50) | DDB1CRBNNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-1537066-B1 | CYCLOPENTENONE DERIVATIVES AS POTENT ACTIVATORS OF HSF-1 | BIOGEM S C AR L (IT) | 2017-01-25 | — | — | EP | disclosed |
| US-7183440-B2 | Pharmaceutically useful compounds | CHARTERHOUSE THERAPEUTICS LTD (GB) | 2007-02-27 | — | — | US | disclosed |
| US-20060040869-A1 | Pharmaceutically useful compounds | BIOGEM S.C.A.R.L. (IT) | 2006-02-23 | — | — | US | disclosed |
| EP-1537066-A2 | IMPROVEMENTS IN PHARMACEUTICALLY USEFUL COMPOUNDS | Charterhouse Therapeutics Ltd. (GB) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004013077-A2 | CYCLOPENTANONE AND CYCLOPENTANONE DERIVATIVES AS POTENT ACTIVATORS OF HSF-1 | CHARTERHOUSE THERAPEUTICS LTD (GB) | 2004-02-12 | — | — | WO | disclosed |
| EP-0214009-A2 | Enaminones as potential prodrugs of primary and secondary amines | MERCK & CO. INC. (US) | 1987-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040869-A1 | Pharmaceutically useful compounds | MC2R, CRKL, NPY2R | DDB1 4665/4885CRBN 155/4885NFKB1 2975/4885 |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | DDB1 4531/4885CRBN 4685/4885NFKB1 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.